Immuno-Resistance and Sequencing Symposium

Immuno-Resistance and Sequencing Symposium

A Pre-Conference Program; additional registration is required.

Thursday, Nov. 11, 2021*
7:30 a.m.–6 p.m. EST

*Dates and times subject to change. 

Program Purpose

While immunotherapy treatments, particularly anti-PD-1 therapies, have improved outcomes for some patients, the issue of post-treatment relapse remains a large problem. The proper choice of treatment after relapse on checkpoint inhibition is, therefore, a critical issue to solve. This symposium will explore the preclinical and clinical data on sequencing of immunotherapies, in order to improve patient outcomes and ensure the field of immunotherapy remains at the forefront of oncology care.

Program Organizers

  • Elizabeth M. Jaffee, MD Sidney Kimmel Cancer Center, Johns Hopkins University
  • Samir N. Khleif, MD   Georgetown University Medical Center
  • Ira Mellman, PhD –  Genentech, Inc.
  • Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center

Target Audience

The target audience for this symposium includes basic, translational, and clinical researchers from all work settings with an interest in the biological foundation of resistance to immune checkpoint inhibitors and methods to overcome this.

Learning Objectives

At the conclusion of this activity, participants should be able to:

    • Describe the current understanding of resistance to and relapse on checkpoint inhibitor therapies
    • Outline the biological fundamentals of immunotherapy sequencing and the effects on the immune profile and tumor microenvironment
    • Summarize clinical advancements in sequencing of immune therapies for cancer
SITC's Immune-Resistance and Sequencing Symposium is supported in part by grants from Alkermes, Inc., Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. and Pfizer, Inc.

Program Schedule*
*Program schedule subject to change. 

Session I: Novel Primary vs. Adaptive Resistance Mechanisms
7:30–9:15 a.m. EST

7:30 a.m.
Samir N. Khleif, MD – Georgetown University Medical Center

7:35 a.m.  Anti-PD1 Resistance – Different Flavors
Samir N. Khleif, MD – Georgetown University Medical Center

7:55 a.m.  Dissecting the Complexity of HLA Loss in Cancer
Christian Hammer, PhD – Genentech, Inc. 

8:15 a.m.  Dissecting Evolution of Clinical Immunotherapy Resistance
David Liu, MD, MPH, MS Dana-Farber Cancer Institute
8:35 a.m. Immune Checkpoint Therapy: Identification of Resistance Mechanisms
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
8:55 a.m. Session I Panel Discussion 
Ira Mellman, PhD – Genentech, Inc.
Session I Speakers
                  Michael B. Atkins, MD - Georgetown Lombardi Comprehensive Cancer

9:15 a.m. Break

Session II: Myths vs. Knowledge on Clinical Therapeutic Mechanisms – Lessons Learned
9:30–11:10 a.m. EST

9:30 a.m. Single Agent Trials, Lessons Learned - OX40 Agonists are Still Alive
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center

9:50 a.m. Role of Tim3 in Myeloid Cells
Vijay K. Kuchroo, DVM, PhD – Center for Neurologic Diseases, BWH

10:10 a.m. Anti-PD1 and IDO1 Inhibition:  Lessons Learned
Lance Leopold, MD – Incyte

10:30 a.m. Priming the Immune System to Provoke Checkpoints: The Path to Maintaining the Immunotherapy Momentum
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

10:50 a.m. Session II Panel Discussion 
Padmanee Sharma, MD, PhD – The University of Texas MD Anderson Cancer Center
Session II Speakers

Session III: Understanding the Biology of Therapeutic Pillars – Targeted Pathways and Future Direction
11:10 a.m.–2:20 p.m. EST

11:10 a.m. VISTA Targeting of T cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
J. Louise Lines, PhD – Dartmouth College

11:30 a.m. Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy
Dimitros Skokos, PhD – Regeneron Pharmaceuticals, Inc.

11:50 a.m. Lunch Break

1:20 p.m. In Pre-clinical Models Metabolic Manipulations Improve the Efficacy of T cell Immunotherapy of Melanoma
Hildegund Ertl, MD - The Wistar Institute

1:40 p.m. T Cell Signaling - Reprogramming Epigenetic
E. John Wherry, PhD – University of Pennsylvania

2:00 p.m.
Session III Panel Discussion
Session III Speakers

Session IV: Resistance Reversal Strategies & Sequencing
2:20–4:20 p.m. EST

2:20 p.m. Cellular Mechanisms of Cancer Immunity Response and Resistance
Ira Mellman, PhD – Genentech, Inc.

2:40 p.m. T cell Activation and Timing 

3 p.m. Mapping Immunosuppressive Cell in the Tumor Microenvironment
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

3:20 p.m. Discovering Resistance – Single-Cell Analyses

3:40 p.m. Autophagy and Immunometabolism Regulation of CD8+ T cell Antitumor Immunity
Julian J. Lum, PhD – BC Cancer

4 p.m. Session IV Panel Discussion – Rational Combination Design
Samir N. Khleif, MD – Georgetown University Medical Center
Session IV Speakers

4:20 p.m. Break

Session V: Developmental Process
4:35–6 p.m. EST

 4:35 p.m. Novel Immunotherapy Clinical Trial Design
Osama E. Rahma, MD – Dana-Farber Cancer Institute

4:55 p.m. Combinations of Agents without Single-agent Activity
Kald Abdallah, MD, PhD – Bristol Myers Squibb

5:15 p.m. Regulatory Considerations for Cancer Immunotherapeutic Development – anti-PD-(L)1 resistance
Marc Theoret, MD – Food and Drug Administration (FDA)

5:35 p.m. Session V Panel Discussion
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University
Session V Speakers

5:55 p.m. Closing Remarks
Samir N. Khleif, MD – Georgetown University Medical Center

SITC Related Resources

SITC offers a variety of resources about immunology and immunotherapy. Explore the pages below to learn more.